e-Drug3D

2157

VIMSELTINIB

INN
VIMSELTINIB

cas 1628606-05-2

CLASS

CASS ANTINEOPLASTIC
KINASE INHIBITOR
TREATMENT OF SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

ROUTE (list)

ORAL

ATC code

PK parameters

Tmax 1 HOUR
VD 90 LITER
Cl 0.5 LITER / HOUR
PPB 96.5 PERCENT
t1/2 144 HOUR

Solubility

VERY SLIGHTLY SOLUBLE IN WATER

Target

TARGET COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R)

PDB
7MFC (CRYSTAL STRUCTURE OF CSF1R IN COMPLEX WITH VIMSELTINIB)

Download experimental 3D coordinates of Z6V with added hydrogens

Download SDF file

4(3H)-Pyrimidinone, 3-methyl-2-[(1-methylethyl)amino]-5-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]- (ACI)

Formula:
C23H25N7O2

Calculated chemical properties:

MW 431.50
NB_atoms 32
XLogP 3.56
PSA 81.796
NB_HD 1
NB_HA 9
fsp3 0.26
Lipinski(0=no;1=yes) 1

FDA
NDA 219304 (pdf not found) INN (VIMSELTINIB) ROMVIMZA (DECIPHERA PHARMS) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY